All In Biotech

Drug Trial Radar · NCT03333343

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

A Phase Ib, Open Label, Multi-center Study to Characterize the Safety, Tolerability and Preliminary Efficacy of EGF816 in Combination With Selected Targeted Agents in EGFR Mutant NSCLC

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

105

Actual

Start

Jan 29, 2018

Primary completion

Jul 12, 2027

Study completion Jul 12, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 6, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study purpose is to evaluate the safety, tolerability, and preliminary efficacy of the addition of INC280, trametinib, ribociclib, gefitinib, or LXH254 to EGF816 in adult patients with advanced Epidermal growth factor receptor- mutant (EGFR-mutant) non-small cell lung cancer (NSCLC).

Conditions

  • EGFR-mutant Non-small Cell Lung Cancer

Interventions

  • EGF816Drug

    Study Drug

  • trametinibDrug

    Study Drug

  • ribociclibDrug

    Study Drug

  • LXH254Drug

    Study Drug

  • INC280Drug

    Study Drug

  • gefitinibDrug

    Study Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with adverse events and serious adverse eventsTime frame: Every day until study end, approximately 4 years
  2. Number of participants with DLTs in the first cycle of combination (Dose escalation only)Time frame: 28 days
  3. Number of participants with dose interruptions and reductionsTime frame: From first dose until study ends, approximately 4 years
  4. Dose intensity of study drugsTime frame: From first dose until study ends, approximately 4 years
  5. ORR2Time frame: Every 8-12 weeks until study ends, approximately 4 years

Locations

11 sites in 6 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Cologne, North Rhine-Westphalia, Germany

  • Novartis Investigative Site

    Hong Kong, Hong Kong

  • Novartis Investigative Site

    Ancona, AN, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Rozzano, MI, Italy

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Tainan, Taiwan

  • Novartis Investigative Site

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.